Chinese
英语

Resource Language

资源语种

Publication time

发布时间

Sort By排序

共检索5条数据Total:5

2020-02-20

Department of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine,; 100850 Beijing, P. R. China 0000 0004 0369 153Xgrid.24696.3fSchool of Nursing, Capital Medical University,; 100069 Beijing, P. R. China grid.440208.aDepartment of Pharmacy, Hebei General Hospital, 050000 Shijiazhuang,; P. R. China 0000 0004 1761 8894grid.414252.4Department of Orthopedics, First Medical Center, ; General Hospital of Chinese PLA, 100853 Beijing, P. R. China grid.412465.0Emergency Department, The Second Affiliated Hospital of Zhejiang; University School of Medicine, 310009 Hangzhou, P. R. China 0000 0004 0368 7223grid.33199.31Emergency Surgery Department, Tongji Hospital; Affiliated to Tongji Medical College, Huazhong University of Science and Technology, 430030 Wuhan, P. R. China Intensive Care Unit, Wuhan Pulmonary Hospital, 430030 Wuhan, P. R. China; 0000 0004 0368 7223grid.33199.31Emergency and Intensive Care Unit, Tongji; Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, 430030 Wuhan, P. R. China Department of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine,; 100850 Beijing, P. R. China

2020-02-20

Department of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine,; 100850 Beijing, P. R. China 0000 0004 0369 153Xgrid.24696.3fSchool of Nursing, Capital Medical University,; 100069 Beijing, P. R. China grid.440208.aDepartment of Pharmacy, Hebei General Hospital, 050000 Shijiazhuang,; P. R. China 0000 0004 1761 8894grid.414252.4Department of Orthopedics, First Medical Center, ; General Hospital of Chinese PLA, 100853 Beijing, P. R. China grid.412465.0Emergency Department, The Second Affiliated Hospital of Zhejiang; University School of Medicine, 310009 Hangzhou, P. R. China 0000 0004 0368 7223grid.33199.31Emergency Surgery Department, Tongji Hospital; Affiliated to Tongji Medical College, Huazhong University of Science and Technology, 430030 Wuhan, P. R. China Intensive Care Unit, Wuhan Pulmonary Hospital, 430030 Wuhan, P. R. China; 0000 0004 0368 7223grid.33199.31Emergency and Intensive Care Unit, Tongji; Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, 430030 Wuhan, P. R. China Department of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine,; 100850 Beijing, P. R. China

2021-10-17

Department of Oncology, The First Affiliated Hospital of USTC, Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, 230021 Hefei, Anhui, China; CAS Center for Excellence in Molecular Cell Sciences, the CAS Key Laboratory of Innate Immunity and Chronic Disease, University of Science and Technology of China, 230027 Hefei, Anhui, China.; Department of Oncology, The First Affiliated Hospital of USTC, Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, 230021 Hefei, Anhui, China; CAS Center for Excellence in Molecular Cell Sciences, the CAS Key Laboratory of Innate Immunity and Chronic Disease, University of Science and Technology of China, 230027 Hefei, Anhui, China.; Department of Oncology, The First Affiliated Hospital of USTC, Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, 230021 Hefei, Anhui, China; CAS Center for Excellence in Molecular Cell Sciences, the CAS Key Laboratory of Innate Immunity and Chronic Disease, University of Science and Technology of China, 230027 Hefei, Anhui, China.; Department of Oncology, The First Affiliated Hospital of USTC, Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, 230021 Hefei, Anhui, China; School of Data Science, University of Science and Technology of China, 230026 Hefei, Anhui, China.; Department of Oncology, The First Affiliated Hospital of USTC, Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, 230021 Hefei, Anhui, China.; Department of Oncology, The First Affiliated Hospital of USTC, Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, 230021 Hefei, Anhui, China.; Department of Oncology, The First Affiliated Hospital of USTC, Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, 230021 Hefei, Anhui, China; School of Life Science and Technology, University of Electronic Science and Technology of China, 610054 Chengdu, Sichuan, China.; Department of Oncology, The First Affiliated Hospital of USTC, Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, 230021 Hefei, Anhui, China; Institute for Advanced Study, Nanchang University, 330031 Nanchang, Jiangxi, China.; Department of Oncology, The First Affiliated Hospital of USTC, Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, 230021 Hefei, Anhui, China.; Department of Oncology, The First Affiliated Hospital of USTC, Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, 230021 Hefei, Anhui, China.; Department of Oncology, The First Affiliated Hospital of USTC, Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, 230021 Hefei, Anhui, China; HanGene Biotech, Xiaoshan Innovation Polis, 31200 Hangzhou, Zhejiang, China.; Department of Oncology, The First Affiliated Hospital of USTC, Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, 230021 Hefei, Anhui, China; CAS Center for Excellence in Molecular Cell Sciences, the CAS Key Laboratory of Innate Immunity and Chronic Disease, University of Science and Technology of China, 230027 Hefei, Anhui, China.; Department of Oncology, The First Affiliated Hospital of USTC, Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, 230021 Hefei, Anhui, China. Electronic address: gchuang@ustc.edu.cn.; Department of Oncology, The First Affiliated Hospital of USTC, Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, 230021 Hefei, Anhui, China; CAS Center for Excellence in Molecular Cell Sciences, the CAS Key Laboratory of Innate Immunity and Chronic Disease, University of Science and Technology of China, 230027 Hefei, Anhui, China; School of Data Science, University of Science and Technology of China, 230026 Hefei, Anhui, China. Electronic address: qukun@ustc.edu.cn.

The mortality risk of coronavirus disease 2019 (COVID-19) patients has been linked to the cytokine storm caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Understanding the inflammatory responses shared between COVID-19 and other infectious diseases that feature cytokine storms may therefore help in developing improved therapeutic strategies. Here, we use integrative analysis of single-cell transcriptomes to characterize the inflammatory signatures of peripheral blood mononuclear cells from patients with COVID-19, sepsis, and HIV infection. We identify ten hyperinflammatory cell subtypes in which monocytes are the main contributors to the transcriptional differences in these infections. Monocytes from COVID-19 patients share hyperinflammatory signatures with HIV infection and immunosuppressive signatures with sepsis. Finally, we construct a "three-stage" model of heterogeneity among COVID-19 patients, related to the hyperinflammatory and immunosuppressive

2020-02-23

Department of Critical Care Medicine, Tongji Medical College, Huazhong University; of Science and Technology, Wuhan, China Department of Critical Care Medicine, Tongji Medical College, Huazhong University; of Science and Technology, Wuhan, China Department of Critical Care Medicine, Tongji Medical College, Huazhong University; of Science and Technology, Wuhan, China Department of Critical Care Medicine, Tongji Medical College, Huazhong University; of Science and Technology, Wuhan, China Jin Yin-tan Hospital, Wuhan, China; Department of Critical Care Medicine, Tongji Medical College, Huazhong University; of Science and Technology, Wuhan, China Department of Critical Care Medicine, Tongji Medical College, Huazhong University; of Science and Technology, Wuhan, China Department of Critical Care Medicine, Xiangyang Central Hospital, Affiliated; Hospital of Hubei University of Arts and Science, Hubei, China Department of Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan,; China Union Hospital, and Department of Critical Care Medicine, Tongji Hospital, Tongji; Medical College, Huazhong University of Science and Technology, Wuhan, China Jin Yin-tan Hospital, Wuhan, China; Department of Critical Care Medicine, Tongji Medical College, Huazhong University; of Science and Technology, Wuhan, China Department of Critical Care Medicine, Tongji Medical College, Huazhong University; of Science and Technology, Wuhan, China Department of Critical Care Medicine, Tongji Medical College, Huazhong University; of Science and Technology, Wuhan, China Department of Critical Care Medicine, Tongji Medical College, Huazhong University; of Science and Technology, Wuhan, China Department of Critical Care Medicine, Tongji Medical College, Huazhong University; of Science and Technology, Wuhan, China

Background: An ongoing outbreak of pneumonia associated with the severe acute respiratory coronavirus 2 (SARS-CoV-2) started in December, 2019, in Wuhan, China. Information about critically ill patients with SARS-CoV-2 infection is scarce. We aimed to describe the clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia. Methods: In this single-centered, retrospective, observational study, we enrolled 52 critically ill adult patients with SARS-CoV-2 pneumonia who were admitted to the intensive care unit (ICU) of Wuhan Jin Yin-tan hospital (Wuhan, China) between late December, 2019, and Jan 26, 2020. Demographic data, symptoms, laboratory values, comorbidities, treatments, and clinical outcomes were all collected. Data were compared between survivors and non-survivors. The primary outcome was 28-day mortality, as of Feb 9, 2020. Secondary outcomes included incidence of SARS-CoV-2-related acute

2020-02-23

Department of Critical Care Medicine, Tongji Medical College, Huazhong University; of Science and Technology, Wuhan, China Department of Critical Care Medicine, Tongji Medical College, Huazhong University; of Science and Technology, Wuhan, China Department of Critical Care Medicine, Tongji Medical College, Huazhong University; of Science and Technology, Wuhan, China Department of Critical Care Medicine, Tongji Medical College, Huazhong University; of Science and Technology, Wuhan, China Jin Yin-tan Hospital, Wuhan, China; Department of Critical Care Medicine, Tongji Medical College, Huazhong University; of Science and Technology, Wuhan, China Department of Critical Care Medicine, Tongji Medical College, Huazhong University; of Science and Technology, Wuhan, China Department of Critical Care Medicine, Xiangyang Central Hospital, Affiliated; Hospital of Hubei University of Arts and Science, Hubei, China Department of Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan,; China Union Hospital, and Department of Critical Care Medicine, Tongji Hospital, Tongji; Medical College, Huazhong University of Science and Technology, Wuhan, China Jin Yin-tan Hospital, Wuhan, China; Department of Critical Care Medicine, Tongji Medical College, Huazhong University; of Science and Technology, Wuhan, China Department of Critical Care Medicine, Tongji Medical College, Huazhong University; of Science and Technology, Wuhan, China Department of Critical Care Medicine, Tongji Medical College, Huazhong University; of Science and Technology, Wuhan, China Department of Critical Care Medicine, Tongji Medical College, Huazhong University; of Science and Technology, Wuhan, China Department of Critical Care Medicine, Tongji Medical College, Huazhong University; of Science and Technology, Wuhan, China

Background: An ongoing outbreak of pneumonia associated with the severe acute respiratory coronavirus 2 (SARS-CoV-2) started in December, 2019, in Wuhan, China. Information about critically ill patients with SARS-CoV-2 infection is scarce. We aimed to describe the clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia. Methods: In this single-centered, retrospective, observational study, we enrolled 52 critically ill adult patients with SARS-CoV-2 pneumonia who were admitted to the intensive care unit (ICU) of Wuhan Jin Yin-tan hospital (Wuhan, China) between late December, 2019, and Jan 26, 2020. Demographic data, symptoms, laboratory values, comorbidities, treatments, and clinical outcomes were all collected. Data were compared between survivors and non-survivors. The primary outcome was 28-day mortality, as of Feb 9, 2020. Secondary outcomes included incidence of SARS-CoV-2-related acute